- Home
- SBUX vs GILD Comparison
SBUX vs GILD Comparison
Compare SBUX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBUX
- GILD
- Stock Information
- Founded
- SBUX 1971
- GILD 1987
- Country
- SBUX United States
- GILD United States
- Employees
- SBUX N/A
- GILD N/A
- Industry
- SBUX Restaurants
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBUX Consumer Discretionary
- GILD Health Care
- Exchange
- SBUX Nasdaq
- GILD Nasdaq
- Market Cap
- SBUX 128.4B
- GILD 119.7B
- IPO Year
- SBUX 1992
- GILD 1992
- Fundamental
- Price
- SBUX $111.75
- GILD $109.95
- Analyst Decision
- SBUX Buy
- GILD Buy
- Analyst Count
- SBUX 24
- GILD 27
- Target Price
- SBUX $105.43
- GILD $101.88
- AVG Volume (30 Days)
- SBUX 11.7M
- GILD 7.9M
- Earning Date
- SBUX 01-28-2025
- GILD 02-11-2025
- Dividend Yield
- SBUX 2.18%
- GILD 2.87%
- EPS Growth
- SBUX N/A
- GILD N/A
- EPS
- SBUX 3.10
- GILD 0.38
- Revenue
- SBUX $36,148,700,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- SBUX $5.88
- GILD $1.72
- Revenue Next Year
- SBUX $7.02
- GILD $3.51
- P/E Ratio
- SBUX $36.05
- GILD $289.34
- Revenue Growth
- SBUX N/A
- GILD 6.04
- 52 Week Low
- SBUX $71.55
- GILD $62.07
- 52 Week High
- SBUX $114.68
- GILD $111.03
- Technical
- Relative Strength Index (RSI)
- SBUX 66.84
- GILD 75.82
- Support Level
- SBUX $111.62
- GILD $94.56
- Resistance Level
- SBUX $113.47
- GILD $106.69
- Average True Range (ATR)
- SBUX 2.05
- GILD 2.29
- MACD
- SBUX -0.27
- GILD 1.15
- Stochastic Oscillator
- SBUX 68.05
- GILD 93.47
About SBUX Starbucks Corporation
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).